JP2022525478A5 - - Google Patents

Info

Publication number
JP2022525478A5
JP2022525478A5 JP2021556493A JP2021556493A JP2022525478A5 JP 2022525478 A5 JP2022525478 A5 JP 2022525478A5 JP 2021556493 A JP2021556493 A JP 2021556493A JP 2021556493 A JP2021556493 A JP 2021556493A JP 2022525478 A5 JP2022525478 A5 JP 2022525478A5
Authority
JP
Japan
Prior art keywords
sequence
binding protein
bispecific antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021556493A
Other languages
English (en)
Japanese (ja)
Other versions
JP7682797B2 (ja
JP2022525478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023986 external-priority patent/WO2020191344A1/en
Publication of JP2022525478A publication Critical patent/JP2022525478A/ja
Publication of JP2022525478A5 publication Critical patent/JP2022525478A5/ja
Priority to JP2025080864A priority Critical patent/JP2025122027A/ja
Application granted granted Critical
Publication of JP7682797B2 publication Critical patent/JP7682797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556493A 2019-03-20 2020-03-20 クローディン６二重特異性抗体 Active JP7682797B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080864A JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン６二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821399P 2019-03-20 2019-03-20
US62/821,399 2019-03-20
PCT/US2020/023986 WO2020191344A1 (en) 2019-03-20 2020-03-20 Claudin-6 bispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080864A Division JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン６二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2022525478A JP2022525478A (ja) 2022-05-16
JP2022525478A5 true JP2022525478A5 (https=) 2023-03-29
JP7682797B2 JP7682797B2 (ja) 2025-05-26

Family

ID=72521273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556493A Active JP7682797B2 (ja) 2019-03-20 2020-03-20 クローディン６二重特異性抗体
JP2025080864A Pending JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン６二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080864A Pending JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン６二重特異性抗体

Country Status (6)

Country Link
US (1) US20220177583A1 (https=)
EP (1) EP3941944A4 (https=)
JP (2) JP7682797B2 (https=)
CN (1) CN114206934A (https=)
CA (1) CA3134056A1 (https=)
WO (1) WO2020191344A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3941946T3 (da) 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
UY39507A (es) * 2020-11-06 2022-03-31 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
KR20230154317A (ko) * 2021-03-05 2023-11-07 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. 항-cldn6 항체 및 이의 용도
US11739144B2 (en) * 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
AU2022270717A1 (en) * 2021-05-07 2023-12-14 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
IL309495A (en) * 2021-07-15 2024-02-01 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
US20240368282A1 (en) * 2021-09-01 2024-11-07 Biosceptre (Aust) Pty Ltd Methods and compositions for stimulating immune activity
EP4395823A4 (en) * 2021-09-03 2025-07-16 Novarock Biotherapeutics Ltd BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN
WO2023053282A1 (ja) * 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
WO2024227427A1 (en) * 2023-04-29 2024-11-07 Innovent Biologics (Suzhou) Co., Ltd. Modified antibodies, antibody fragments thereof, and antibody-drug conjugates
IL324834A (en) 2023-05-25 2026-01-01 Univ California Dosage of claudin-6 conjugates for cancer treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581916A (en) 1897-05-04 Harvester
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
EP0184365B1 (en) 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
DK0418099T3 (da) 1989-09-15 2002-04-02 Res Triangle Inst Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6407115B1 (en) 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
DK0871490T3 (da) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
AU756796B2 (en) 1998-10-16 2003-01-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Combination therapy with VIP antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
BR0313197A (pt) 2002-08-02 2005-08-09 Immunogen Inc Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
AU2003279842A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
ES2989943T3 (es) 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
JP6499079B2 (ja) * 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
ES2875274T3 (es) 2015-11-02 2021-11-10 Hoffmann La Roche Procedimientos de preparación de formas fucosiladas y afucosiladas de una proteína
NO20210351A1 (en) * 2017-09-18 2021-03-18 Univ California Claudin6 antibodies and methods of treating cancer

Similar Documents

Publication Publication Date Title
JP2022525478A5 (https=)
JP7773528B2 (ja) 抗ｃｄ２８組成物
JP2022541435A5 (https=)
Godar et al. Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
JP5851419B2 (ja) ヘテロダイマー結合タンパク質およびその使用
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法
JP2023516004A5 (https=)
CN113150156B (zh) 抗tigit抗体及其用途
US20230303720A1 (en) Formulations for protein therapeutics
JP7592712B2 (ja) ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
WO2023201309A1 (en) Antibodies that bind pd-l1, pd-l2 and/or cd28
JP2025512953A5 (https=)
JP2023516941A5 (https=)
CN115279412A (zh) 偶联脂肪酸分子的抗体及其用途
US20240124574A1 (en) Bispecific Antibodies with Charge Pairs and Uses Thereof
TW202241967A (zh) 基於茚地那韋的化學二聚化ｔ細胞銜接器組成物
KR20250173599A (ko) 항-cd28 조성물
US20250101104A1 (en) Bispecific molecule with tunable affinity to a targeted antigen
JP2026027248A (ja) 抗原結合分子およびその使用
JP2024541476A5 (https=)
JP2024508597A5 (https=)
JP2026514029A (ja) 抗ｃｄ２８×抗ｔｒｏｐ２抗体
HK40082596A (en) Antibodies conjugated with fatty acid molecules and uses thereof
Kiprijanov Bispecific antibodies and immune therapy targeting